Ira Studin, PhD

The argument for weighing clinical points more heavily in the access equation.

Demonstrating clinical benefit is the ultimate gateway to smoother patient access.

A value deficit and potential consumer value proposition.

One, tackle by price; the other, tackle with data.

Leverage priorities in preclinical business planning.

A strategic formulation for separate IDN market spaces.

Payers won’t let these products break the bank.

Conditions require a disciplined approach to drug pricing.

Shift focus in orphan and ultra-orphan messaging to clinical benefit.

Supporting health plan clinical preparation and financial modeling.

Different paths to formulary decision-making.

Reversing non-formulary status will usually require new data.

Tackling the subjective limits of value proposition.

Payers not looking to favor one product.

Potential for quality equivalent to economies of scale.

Emerging limits of one-year payer time frames.

Initial coverage discussions put the focus on three key factors.

A business framework for pricing and broader brand strategy.

Writing at the intersection of managed markets and the pharmaceutical industry.

How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid an industrywide crisis.

Ira Studin takes a look at how pharma manufacturers can address extreme pricing and build legitimacy into commercialization to avoid an industry-wide crisis.

The marketing challenge for every business is to sell products against a backdrop of competitive forces, technological developments, and established industry rules. While change is a constant, the natural tendency within each of these zones is to operate in some kind of normalcy, and for the relationships among them to interact in equilibrium. There are times, of course, when profound change occurs. These might be called "tipping points," where the weight of something new overwhelms the established logic.